Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma

Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined w...

Full description

Bibliographic Details
Main Authors: YU Xuxu, LI Xiangke, YANG Minjie, CHEN Zhong, MAO Yinggang, SONG Lijie
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2021-10-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
Online Access:http://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0271.htm